ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $877,716 | -81.8% | 19,027 | -84.2% | 0.00% | -83.3% |
| Q1 2023 | $4,831,007 | +21.5% | 120,474 | +40.4% | 0.02% | +9.1% |
| Q4 2022 | $3,976,689 | +442.5% | 85,834 | +385.1% | 0.02% | +450.0% |
| Q3 2022 | $733,000 | -61.6% | 17,695 | -32.7% | 0.00% | -63.6% |
| Q1 2022 | $1,910,000 | -52.5% | 26,295 | -45.0% | 0.01% | -50.0% |
| Q4 2021 | $4,021,000 | +279.3% | 47,816 | +306.8% | 0.02% | +214.3% |
| Q3 2021 | $1,060,000 | -60.9% | 11,754 | -58.7% | 0.01% | -63.2% |
| Q2 2021 | $2,713,000 | +417.7% | 28,456 | +518.3% | 0.02% | +375.0% |
| Q1 2021 | $524,000 | -67.3% | 4,602 | -60.3% | 0.00% | -69.2% |
| Q4 2020 | $1,604,000 | +82.7% | 11,585 | +8.5% | 0.01% | +85.7% |
| Q3 2020 | $878,000 | -5.0% | 10,681 | -50.6% | 0.01% | -61.1% |
| Q4 2019 | $924,000 | -34.9% | 21,635 | +17.1% | 0.02% | -52.6% |
| Q2 2018 | $1,420,000 | – | 18,470 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |